Editas Medicine Inc
SWB:8EM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Editas Medicine Inc
SWB:8EM
|
US |
|
E
|
EFG International AG
SWB:E2S
|
CH |
|
S
|
Shabbir Tiles and Ceramics Ltd
KAR:STCL
|
PK |
|
D
|
DSJ Keep Learning Ltd
BSE:526677
|
IN |
|
Extreme Biodiesel Inc
OTC:XTRM
|
US |
|
Aranjin Resources Ltd
F:5D5
|
CA |
|
Smalto SA
PAR:MLSML
|
FR |
|
Vestand Inc
OTC:VSTD
|
US |
|
Spanish Broadcasting System Inc
OTC:SBSAA
|
US |
|
O
|
Onward Technologies Ltd
NSE:ONWARDTEC
|
IN |
|
Iren SpA
OTC:IRDEF
|
IT |
|
A
|
Avicopter PLC
SSE:600038
|
CN |
|
Sundy Land Investment Co Ltd
SSE:600077
|
CN |
|
T
|
Topaz Energy Corp
F:5XU
|
CA |
|
Beter Bed Holding NV
F:BBQ
|
NL |
|
Ampd Ventures Inc
F:2Q0
|
CA |
|
D
|
Dril-Quip Inc
F:DQU
|
US |
|
Rakumo Inc
TSE:4060
|
JP |
|
F
|
First Elite Capital Modaraba
KAR:FECM
|
PK |
Wall St Price Targets
8EM Price Targets Summary
Editas Medicine Inc
According to Wall Street analysts, the average 1-year price target for
8EM is 5.06 EUR with a low forecast of 0.86 EUR and a high forecast of 13.37 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 8EM's stock price target?
Price Target
5.06
EUR
According to Wall Street analysts, the average 1-year price target for
8EM is 5.06 EUR with a low forecast of 0.86 EUR and a high forecast of 13.37 EUR.
What is the Revenue forecast for Editas Medicine Inc?
Projected CAGR
21%
The compound annual growth rate for Revenue over the next 8 years is 21%.